General Information of DTT (ID: TTDCVZW)

DTT Name Gamma-aminobutyric acid B receptor (GABBR) DTT Info
Gene Name GABBR1

Molecule-Related Drug & Molecule List

Molecule-Related Drug List
Molecule Type:
DTT
DTP
DME
Drug Status:
Discontinued Drug(s)
Approved Drug(s)
Clinical Trial Drug(s)
Preclinical Drug(s)
Investigative Drug(s)
4 Approved Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
Baclofen DM0QV1J Multiple sclerosis 8A40 Approved [1]
Gabapentin DM6T924 Complex partial seizure 8A68.0 Approved [2]
Gamma Hydroxybutyric Acid DMGBKVD Narcolepsy 7A20 Approved [3]
Progabide DM671NG Depression 6A70-6A7Z Approved [4]
------------------------------------------------------------------------------------
7 Clinical Trial Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
Arabaclofen DMZB9RI Fragile X syndrome LD55 Phase 3 [5]
Arbaclofen placarbil DMO628K Fragile X syndrome LD55 Phase 3 [6]
[3H](R)-(-)-baclofen DMLRHM5 Multiple sclerosis 8A40 Phase 3 [7]
ASP8062 DMR1MIV Fibromyalgia MG30.01 Phase 2 [8]
GSK683699 DMTW79H Inflammatory bowel disease DD72 Phase 2 [9]
SGS742 DM5XYFH Schizophrenia 6A20 Phase 2 [10]
SSTarbaclofen DMRGTZ2 Autism spectrum disorder 6A02 Phase 2 [11]
------------------------------------------------------------------------------------
⏷ Show the Full List of 7 Clinical Trial Drug(s)
5 Discontinued Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
SUN-09 DMMG47P Hypertonia KB08.1 Discontinued in Phase 3 [12]
AZD3355 DMT5ZK3 Gastroesophageal reflux disease DA22.Z Discontinued in Phase 2 [13]
AZD-9343 DM1ZVO3 Gastroesophageal reflux disease DA22.Z Discontinued in Phase 1 [14]
CGP-35348 DMZM70X Epilepsy 8A60-8A68 Terminated [16]
SCH 50911 DMW9H4A Absence seizure 8A68.2 Terminated [17]
------------------------------------------------------------------------------------
1 Preclinical Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
ADX-71943 DMEWFOL Gastroesophageal reflux disease DA22.Z Preclinical [15]
------------------------------------------------------------------------------------
43 Investigative Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
((E)-3-Amino-propenyl)-methyl-phosphinic acid DMEJRVW Discovery agent N.A. Investigative [18]
((Z)-3-Amino-propenyl)-methyl-phosphinic acid DM6H0FW Discovery agent N.A. Investigative [18]
(3-Amino-1-ethyl-propyl)-methyl-phosphinic acid DMPHCX7 Discovery agent N.A. Investigative [18]
(3-Amino-1-hydroxy-propyl)-methyl-phosphinic acid DM7HF4I Discovery agent N.A. Investigative [18]
(3-Amino-phenyl)-phosphonic acid diphenyl ester DMDGFS0 Discovery agent N.A. Investigative [19]
(3-Amino-propyl)-hexyl-phosphinic acid DMBJYTD Discovery agent N.A. Investigative [20]
(3-Amino-propyl)-hydroxymethyl-phosphinic acid DMGFIJV Discovery agent N.A. Investigative [18]
(3-Amino-propyl)-phosphonic acid DMK3JZS Discovery agent N.A. Investigative [19]
(R)-5-Amino-3-(4-chloro-phenyl)-pentanoic acid DMW87OE Discovery agent N.A. Investigative [1]
2-hydroxy-saclofen DMHO8KQ Discovery agent N.A. Investigative [21]
3-ammoniopropane-1-sulfinate DM5SQVC Discovery agent N.A. Investigative [22]
4-Amino-3-(2-chloro-phenyl)-butyric acid DMIX81A Discovery agent N.A. Investigative [9]
4-Amino-3-(4-fluoro-phenyl)-butyric acid DMVKPF1 Discovery agent N.A. Investigative [9]
4-Amino-3-(5-bromo-thiophen-2-yl)-butyric acid DMTO8NV Discovery agent N.A. Investigative [9]
4-Amino-3-(5-chloro-thiophen-2-yl)-butyric acid DM415DB Discovery agent N.A. Investigative [9]
4-Amino-3-(5-methyl-thiophen-2-yl)-butyric acid DMEDRAX Discovery agent N.A. Investigative [9]
4-Amino-3-benzofuran-2-yl-butyric acid DM1IHCV Discovery agent N.A. Investigative [23]
4-Amino-3-thiophen-2-yl-butyric acid DMZJS2E Discovery agent N.A. Investigative [9]
amino-propylphosphinic acid DMT5HOA Discovery agent N.A. Investigative [7]
AVE-1876 DMC0PY5 Discovery agent N.A. Investigative [24]
BHF-177 DMP21ST Anxiety disorder 6B00-6B0Z Investigative [25]
CGP 46381 DMXV6RD Discovery agent N.A. Investigative [26]
CGP 47656 DME39UQ Discovery agent N.A. Investigative [21]
CGP 54626A DMEHYVS Discovery agent N.A. Investigative [27]
CGP 55845 DMNMG0I Discovery agent N.A. Investigative [26]
CGP 56999A DMR708D Discovery agent N.A. Investigative [21]
CGP 62349 DMYXE39 Discovery agent N.A. Investigative [28]
CGP 64213 DMR8U1M Discovery agent N.A. Investigative [21]
CGP 71872 DMJWED7 Discovery agent N.A. Investigative [21]
CGP-29030A DMS61KA Pain MG30-MG3Z Investigative [29]
CGP-34938 DM84TSH Discovery agent N.A. Investigative [18]
CGP-35024 DMHKETG Discovery agent N.A. Investigative [30]
CGP-35582 DM3J6HM Discovery agent N.A. Investigative [18]
CGP-36216 DM9U8TO Discovery agent N.A. Investigative [20]
CGP-44532 DMKF0GH Drug abuse 6C4G.1Z Investigative [31]
GABA-B receptor PAM DMOF7JL Anxiety disorder 6B00-6B0Z Investigative [25]
Phaclofen DMALRCH Discovery agent N.A. Investigative [32]
PMID25050158C14 DMRFQ1W Discovery agent N.A. Investigative [33]
saclofen DM3TO27 Discovery agent N.A. Investigative [21]
TG-3030 DM8RSDE Nicotine dependence 6C4A.2 Investigative [25]
[125I]CGP 64213 DMIAO4V Discovery agent N.A. Investigative [34]
[125I]CGP 71872 DMQVW4E Discovery agent N.A. Investigative [21]
[3H]CGP27492 DMQTBRM Discovery agent N.A. Investigative [20]
------------------------------------------------------------------------------------
⏷ Show the Full List of 43 Investigative Drug(s)
Molecule Interaction Atlas

References

1 Synthesis and pharmacology of the baclofen homologues 5-amino-4-(4-chlorophenyl)pentanoic acid and the R- and S-enantiomers of 5-amino-3-(4-chlorop... J Med Chem. 1999 Jun 3;42(11):2053-9.
2 Gabapentin increases a tonic inhibitory conductance in hippocampal pyramidal neurons. Anesthesiology. 2006 Aug;105(2):325-33.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
4 Interactions between dopamine and GABA in the control of ambulatory activity and neophobia in the mouse. Pharmacol Biochem Behav. 1998 Jan;59(1):239-47.
5 Impact of acamprosate on behavior and brain-derived neurotrophic factor: an open-label study in youth with fragile X syndrome. Psychopharmacology (Berl). 2013 Jul;228(1):75-84.
6 Arbaclofen placarbil, a novel R-baclofen prodrug: improved absorption, distribution, metabolism, and elimination properties compared with R-baclofen.J Pharmacol Exp Ther.2009 Sep;330(3):911-21.
7 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 242).
8 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
9 3-Thienyl- and 3-furylaminobutyric acids. Synthesis and binding GABAB receptor studies. J Med Chem. 1991 Aug;34(8):2557-60.
10 SGS742: the first GABA(B) receptor antagonist in clinical trials. Biochem Pharmacol. 2004 Oct 15;68(8):1479-87.
11 Reversal of disease-related pathologies in the fragile X mouse model by selective activation of GABAB receptors with arbaclofen. Sci Transl Med. 2012 Sep 19;4(152):152ra128.
12 The effects of the GABA agonist, baclofen, on sleep and breathing. Eur Respir J. 1995 Feb;8(2):230-4.
13 Efficacy and safety of lesogaberan in gastro-oesophageal reflux disease: a randomised controlled trial.Gut.2013 Sep;62(9):1248-55.
14 The GABA(B) receptor agonist AZD9343 inhibits transient lower oesophageal sphincter relaxations and acid reflux in healthy volunteers: a phase I study. Aliment Pharmacol Ther. 2009 Nov 1;30(9):937-46.
15 Evaluation of peripheral versus central effects of GABA(B) receptor activation using a novel, positive allosteric modulator of the GABA(B) receptor ADX71943, a pharmacological tool compound with a fully peripheral activity profile. Br J Pharmacol. 2014 Nov;171(21):4941-54.
16 The selective GABAB antagonist CGP-35348 blocks spike-wave bursts in the cholesterol synthesis rat absence epilepsy model. Brain Res. 1996 Aug 12;729(2):147-50.
17 Activation of nigral dopamine neurons by the selective GABA(B)-receptor antagonist SCH 50911. J Neural Transm. 1999;106(5-6):383-94.
18 Phosphinic acid analogues of GABA. 1. New potent and selective GABAB agonists. J Med Chem. 1995 Aug 18;38(17):3297-312.
19 Phosphorus analogues of gamma-aminobutyric acid, a new class of anticonvulsants. J Med Chem. 1984 May;27(5):654-9.
20 Biological activity of 3-aminopropyl (methyl) phosphinic acid, a potent and selective GABAB agonist with CNS activity, Bioorg. Med. Chem. Lett. 3(4):515-518 (1993).
21 Expression cloning of GABA(B) receptors uncovers similarity to metabotropic glutamate receptors. Nature. 1997 Mar 20;386(6622):239-46.
22 A study of 3-amino-N-hydroxypropanesulfonamide derivatives as potential GABAB agonists and their fragmentation to 3-aminopropanesulfinic acid, Bioorg. Med. Chem. Lett. 6(14):1709-1714 (1996).
23 Synthesis and pharmacological evaluation of gamma-aminobutyric acid analogues. New ligand for GABAB sites. J Med Chem. 1987 Apr;30(4):743-6.
24 Company report (Sanofi)
25 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 241).
26 The human GABA(B1b) and GABA(B2) heterodimeric recombinant receptor shows low sensitivity to phaclofen and saclofen. Br J Pharmacol. 2000 Nov;131(6):1050-4.
27 GABA(B) receptors function as a heteromeric assembly of the subunits GABA(B)R1 and GABA(B)R2. Nature. 1998 Dec 17;396(6712):674-9.
28 Characterisation and partial purification of the GABA(B) receptor from the rat cerebellum using the novel antagonist [3H]CGP 62349. Brain Res Mol Brain Res. 1999 Aug 25;71(2):279-89.
29 Effects of a novel piperazine derivative (CGP 29030A) on nociceptive dorsal horn neurons in the rat. Drugs Exp Clin Res. 1992;18(11-12):447-59.
30 Inhibition of transient LES relaxations and reflux in ferrets by GABA receptor agonists. Am J Physiol. 1999 Oct;277(4 Pt 1):G867-74.
31 Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17.
32 Astrocytes and interneurons in memory processing in the chick hippocampus: roles for G-coupled protein receptors, GABA(B) and mGluR1. Neurochem Res. 2009 Oct;34(10):1712-20.
33 Discovery of a Negative Allosteric Modulator of GABAB Receptors. ACS Med Chem Lett. 2014 May 27;5(7):742-7.
34 Ca(2+) requirement for high-affinity gamma-aminobutyric acid (GABA) binding at GABA(B) receptors: involvement of serine 269 of the GABA(B)R1 subunit. Mol Pharmacol. 2000 Mar;57(3):419-26.